Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT00430625
First received: February 1, 2007
Last updated: February 19, 2014
Last verified: February 2014
  Purpose

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the efficacy of every other week dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of 45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.


Condition Intervention Phase
Gaucher Disease, Type 1
Biological: VPRIV ®,
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group. [ Time Frame: Week 53 ] [ Designated as safety issue: No ]
    Efficacy endpoint


Secondary Outcome Measures:
  • Change From Baseline to 12 Months in Hemoglobin Concentration in 45 U/kg Treatment Group [ Time Frame: Week 53 ] [ Designated as safety issue: No ]
  • Change From Baseline to 12 Months in Platelet Counts for Each Treatment Group. [ Time Frame: Week 53 ] [ Designated as safety issue: No ]
    intent to treat (ITT) Population

  • Change From Baseline to 12 Months in Normalized Liver Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI) [ Time Frame: Week 51 ] [ Designated as safety issue: No ]
    Liver Volume has been normalized for percentage of body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cc]/Body weight [kg])*100

  • Change From Baseline to 12 Months in Normalized Spleen Volume (Percent Body Weight) for Each Treatment Group (Measured by Magnetic Resonance Imaging (MRI)) [ Time Frame: Week 51 ] [ Designated as safety issue: No ]
    12 patients in the 60 U/kg group and 13 patients in the 45 U/kg group were analyzed for efficacy in the intent to treat (ITT) population. Spleen Volume has been normalized for percent of body weight for each treatment arm. Spleen size relative to body weight = (Spleen volume [cc]/Body weight [kg])*100

  • Percent Change From Baseline to 12 Months in Plasma Chitotriosidase for Each Treatment Group [ Time Frame: Week 53 ] [ Designated as safety issue: No ]
    Percent Change from Baseline to Weeks 53 by Randomized velaglucerase alfa Treatment Group - Subset of intent to treat (ITT) Population who were wild type homozygous for chitotriosidase.

  • Percent Change From Baseline to 12 Months in Chemokine (C-C Motif) Ligand 18 (CCL18) [ Time Frame: Week 53 ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: January 2007
Study Completion Date: May 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: VPRIV®-45 U/kg, IV, every other week
VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
Biological: VPRIV ®,
Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
Other Names:
  • VPRIV®
  • velaglucerase alfa
  • GA-GCB
  • Gene-activated® human glucocerebrosidase
Experimental: VPRIV®-60 U/kg, IV, every other week
VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
Biological: VPRIV ®,
Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
Other Names:
  • VPRIV®
  • velaglucerase alfa
  • GA-GCB
  • Gene-activated® human glucocerebrosidase

Detailed Description:

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the Central Nervous System (CNS). Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. Velaglucerase alfa contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the efficacy, safety and pharmacokinetics of GA-GCB in men, women, and children with Type 1 Gaucher disease. Each patients duration of treatment was 12 months.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and is willing and able to provide written informed consent prior to initiating any study-related procedures
  • Patient is at least 2 years of age
  • Patient has Gaucher disease-related anemia and
  • Patient has at least moderate splenomegaly or
  • Patient has Gaucher disease-related thrombocytopenia or
  • Patient has a readily palpable enlarged liver
  • Patient has not received treatment for Gaucher disease within 30 months prior to study entry
  • Female patients of child-bearing potential agree to use a medically acceptable method of contraception. Male patients must agree to use a medically acceptable method of birth control.
  • Patient must be sufficiently cooperative to participate in the study as judged by the Investigator.

Exclusion Criteria:

Includes:

  • Patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease
  • Patient is antibody-positive to imiglucerase during screening or has experienced an anaphylactic reaction to imiglucerase
  • Patient has received treatment with any investigational drug or device within the 30 days prior to study entry
  • Patient is Human immunodeficiency virus (HIV) positive
  • Patient is hepatitis positive
  • Patient presents with iron, folic acid and/or vitamin B12 deficiency sustained anemia during screening
  • Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study
  • Patient has a significant comorbidity(ies)that might affect study data or confound the study results
  • Patient is a pregnant and/or lactating female
  • Patient is unable to comply with the protocol or is unlikely to complete the study, as determined by the Investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00430625

Locations
Argentina
Hipolito Yrigoyen
Buenos Aires, Argentina
Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Paraguay
Sociedad Espanola de Socorros Mutuos
Asuncion, Paraguay
Russian Federation
National Research Center for Haematology
Moscow, Russian Federation
Tunisia
La Rabta Hospital
Tunis, Tunisia
Sponsors and Collaborators
Shire
Investigators
Study Director: Kiran Bhirangi, M.D., FRCS Shire Human Genetic Therapies, Inc.
Principal Investigator: Ari Zimran, M.D. Shaare Zedek Medical Center
Principal Investigator: Derlis Emilio Gonzalez Rodriguez, M.D. Sociedad Espanola de Socorros Mutuos
Principal Investigator: Marie-Francoise Ben Dridi, Professor La Rabta Hospital
Principal Investigator: Isaac Kisinovsky, M.D. Hipolito Yrigoyen
Principal Investigator: Elena A. Lukina, Professor National Research Center for Haematology
  More Information

Additional Information:
No publications provided

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT00430625     History of Changes
Other Study ID Numbers: TKT032
Study First Received: February 1, 2007
Results First Received: June 3, 2010
Last Updated: February 19, 2014
Health Authority: United States: Food and Drug Administration
Paraguay: Ministerio de Salud Pública y Bienestar Social
Israel: Ministry of Health
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Russia: Ministry of Health of the Russian Federation
Tunisia: Office of Pharmacies and Medicines

Keywords provided by Shire:
VPRIV®
Enzyme Replacement Therapy
Gaucher disease
glucocerebrosidase
beta-glucocerebrosidase
Acid beta-glucocerebrosidase
glucosylceramidase
D-glucosyl-N-acylsphingosine glucohydrolase
gene activation
human

Additional relevant MeSH terms:
Gaucher Disease
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lipidoses
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Sphingolipidoses

ClinicalTrials.gov processed this record on November 24, 2014